Apomorphine increases vesicular monoamine transporter-2 function: Implications for neurodegeneration

European Journal of Pharmacology

Volumn 492, Issue 2-3, 2004, Pages 143-147

  Truong, Jannine G ^a   Hanson, Glen R ^a   Fleckenstein, Annette E ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Apomorphine; Eticlopride; Neurodegeneration; Redistribution; Vesicular monoamine transporter

Indexed keywords

APOMORPHINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; ETICLOPRIDE; PROTEIN; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE UPTAKE; DRUG EFFECT; DRUG MECHANISM; MALE; NERVE DEGENERATION; NERVE ENDING; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; STRIATE CORTEX; TISSUE DISTRIBUTION;

ANIMALS; APOMORPHINE; BIOLOGICAL TRANSPORT; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGONISTS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NEURODEGENERATIVE DISEASES; RATS; RATS, SPRAGUE-DAWLEY; SYNAPTIC VESICLES; TIME FACTORS; VESICULAR BIOGENIC AMINE TRANSPORT PROTEINS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 2642525951     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.03.060     Document Type: Article

References (25)

1. Battaglia G., Gesi M., Lenzi P., Busceti C.L., Soldani P., Orzi F., Rampello L., Nicoletti F., Ruggieri S., Fornai F. Morphological and biochemical evidence that apomorphine rescues striatal dopamine terminals and prevents methamphetamine toxicity. Ann. N.Y. Acad. Sci. 965:2002;254-266
2. Bedard P.J., Blanchet P.J., Levesque D., Soghomonian J.J., Grondin R., Morissette M., Goulet M., Calon F., Falardeau P., Gomez-Mancilla B., Doucet J.P., Robertson G.S., DiPaolo T. Pathophysiology of L-dopa-induced dyskinesias. Mov. Disord. 14:1999;4-8
3. Blin J., Bonnet A.M., Agid Y. Does levodopa aggravate Parkinson's disease? Neurology. 38:1988;1410-1416
4. Brown J.M., Hanson G.R., Fleckenstein A.E. Cocaine-induced increases in vesicular dopamine uptake: role of dopamine receptors. J. Pharmacol. Exp. Ther. 298:2001;1150-1153
5. Brown J.M., Riddle E.L., Sandoval V., Weston R.K., Hanson J.E., Crosby M.J., Ugarte Y.V., Gibb J.W., Hanson G.R., Fleckenstein A.E. A single methamphetamine administration rapidly decreases vesicular dopamine uptake. J. Pharmacol. Exp. Ther. 302:2002;497-501
6. Dunah A.W., Standaert D.G. Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane. J. Neurosci. 21:2001;5546-5558
7. Fleckenstein A.E., Hanson G.R. Impact of psychostimulants on vesicular monoamine transporter function. Eur. J. Pharmacol. 479:2003;283-289
8. Fornai F., Battaglia G., Gesi M., Orzi F., Nicoletti F., Ruggieri S. Dose-dependent protective effects of apomorphine against methamphetamine-induced nigrostriatal damage. Brain Res. 898:2001;27-35
9. Hyttel J. Age related decreases in the density of dopamine D1 and D2 receptors in corpus striatum of rats. Pharmacol. Toxicol. 61:1987;126-129
10. Jenner P., Olanow W.C. Understanding cell death in Parkinson's disease. Ann. Neurol. 44:1998;S72-S82
11. Kita T., Wagner G.C., Nakashima T. Current research on methamphetamine-induced neurotoxicity: animal models of monoamine disruption. J. Pharmacol. Sci. 92:2003;178-195
12. Kokoshka J.M., Fleckenstein A.E., Wilkins D.G., Hanson G.R. Age-dependent differential responses of monoaminergic systems to high doses of methamphetamine. J. Neurochem. 75:2000;2095-2102
13. Kondo T. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists. J. Neurol. 249:2002;II25-II29
14. Lees A.J. Dopamine agonists in Parkinson's disease: a look at apomorphine. Fundam. Clin. Pharmacol. 7:1993;121-128
15. Marek K., Seibyl J., Shoulson I., Holloway R., Kieburtz K., McDermott M., Kamp C., Shinaman A., Fahn S., Lang A., Weiner W., Welsh M. Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson's disease progression. JAMA. 287:2002;1653-1661
16. Pu C., Vorhees C.V. Developmental dissociation of methamphetamine-induced depletion of dopaminergic terminals and astrocyte reaction in rat striatum. Dev. Brain Res. 72:1993;325-328
17. Riddle E.L., Topham M.K., Haycock J.W., Hanson G.R., Fleckenstein A.E. Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine. Eur. J. Pharmacol. 449:2002;71-74
18. Sandoval V., Riddle E.L., Hanson G.R., Fleckenstein A.E. Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits. J. Pharmacol. Exp. Ther. 304:2002;1181-1187
19. Sandoval V., Riddle E.L., Hanson G.R., Fleckenstein A.E. Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors. J. Neurosci. 22:2002;8705-8710
20. Sun A.Y., Chen Y.M. Oxidative stress and neurodegenerative disorders. J. Biomed. Sci. 5:1998;401-414
21. Symes A.L., Lal S., Sourkes T.L. Time-course of apomorphine in the brain of the immature rat after apomorphine injection. Arch. Int. Pharmacodyn. 223:1976;260-264
22. Teicher M.H., Andersen S.L., Hostetter J.C. Evidence for dopamine receptor pruning between adolescence and adulthood in striatum but not nucleus accumbens. Brain Res. Dev. Brain Res. 89:1995;167-172
23. Truong J.G., Riddle E.L., Sandoval V., Ugarte Y.V., Wilkins D.G., Hanson G.R., Fleckenstein A.E. Impact of age on stimulant-induced alterations in vesicular dopamine transport. Abstract No. 807.1. 2002;Society for Neuroscience, Orlando, FL
24. Truong J.G., Rau K.S., Hanson G.R., Fleckenstein A.E. Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegeneration. Eur. J. Pharmacol. 474:2003;223-226
25. Whone A.L., Remy P., Davis M.R. The REAL-PET study: slower progression in early Parkinson's disease treated with ropinirole compared with L-DOPA. 54th Annual Meeting of the American Academy of Neurology, Denver:2002